Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTC13 in CEA-positive Advanced Malignant Solid Tumors
NCT06821048Phase 1Recruiting
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PTC13 in solid tumor. Primary endpoints: Incidence of Adverse Events at 28 days and Maximum Tolerated Dose at 28 days. Started Jul 2024; status: recruiting.
02
Drugs
PTC13
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06821048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06821048.